Dr. Yardley Discusses CDK4/6 Inhibitors for Breast Cancer

Denise A. Yardley, MD
Published: Monday, Oct 30, 2017



Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.

PALOMA-1 data investigated the clinical science of CDK4/6 inhibitors and demonstrated that they could affect outcomes and double the disease-free survival for patients with hormone receptor-positive breast cancer. The PALOMA-1 trial led to the accelerated approval of palbociclib (Ibrance) in the first-line setting for that patient population.

The confirmatory PALOMA-2 trial further demonstrated that the signal seen with CDK4/6 inhibitors was real and reproducible. PALOMA-3 investigated patients who had failed prior endocrine therapy and then received fulvestrant (Faslodex) with a CDK4/6 inhibitor.
 
SELECTED
LANGUAGE


Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.

PALOMA-1 data investigated the clinical science of CDK4/6 inhibitors and demonstrated that they could affect outcomes and double the disease-free survival for patients with hormone receptor-positive breast cancer. The PALOMA-1 trial led to the accelerated approval of palbociclib (Ibrance) in the first-line setting for that patient population.

The confirmatory PALOMA-2 trial further demonstrated that the signal seen with CDK4/6 inhibitors was real and reproducible. PALOMA-3 investigated patients who had failed prior endocrine therapy and then received fulvestrant (Faslodex) with a CDK4/6 inhibitor.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual Paris Breast Cancer Conference™Dec 31, 20181.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x